On Thursday, AbbVie Inc (NYSE:ABBV)’s shares declined -1.61% to $62.77.
ABBV is currently valued at $105.61 billion. The company has 1.66 billion shares outstanding and 75.10% shares of the company were owned by institutional investors. The company has 4.95 value in price to sale ratio while price to book ratio was recorded as -18.46. The company exchanged hands with 10.24 million shares as compared to its average daily volume of 12.01 million shares.
The mean estimate for the short term price target for AbbVie Inc (NYSE:ABBV) stands at $75.43 according to 14 Analysts. The higher price target estimate for the stock has been calculated at $85.00 while the lower price target estimate is at $56.00.
Analysts mean recommendation for the stock is 2.10. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases.
Zoetis Inc (NYSE:ZTS)’s shares dropped -2.34% to $45.46.
ZTS offered 50.80% EPS for prior five years. The company has 32.80% return on equity value while its ROI ratio was 11.80%. The company has $23.23 billion market capitalizations and the institutional ownership was 93.50%. Its price to book ratio was -19.34. Volatility of the stock was 2.88% for the week while for the month booked as 3.08%.
The mean estimate for the short term price target for Zoetis Inc (NYSE:ZTS) stands at $52.58 according to 12 Analysts. The higher price target estimate for the stock has been calculated at $62.00 while the lower price target estimate is at $45.00.
Analysts mean recommendation for the stock is 1.90. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals.
At the end of Thursday’s trade, DexCom, Inc. (NASDAQ:DXCM)‘s shares dipped -2.57% to $84.81.
DXCM has market value of $6.97 billion while its EPS was booked as $-0.26 in the last 12 months. The stock has 81.29 million shares outstanding while 94.30% shares of the company were owned by institutional investors. In the profitability analysis, the company has gross profit margin of 68.60% while net profit margin was -6.40%. Beta value of the company was 0.40; beta is used to measure riskiness of the security.
The mean estimate for the short term price target for DexCom, Inc. (NASDAQ:DXCM) stands at $100.56 according to 16 Analysts. The higher price target estimate for the stock has been calculated at $120.00 while the lower price target estimate is at $53.00.
Analysts mean recommendation for the stock is 1.80. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
